Counterpoint Mutual Funds LLC Invests $557,000 in Adaptive Biotechnologies Corporation $ADPT

Counterpoint Mutual Funds LLC bought a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 37,214 shares of the company’s stock, valued at approximately $557,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Sound Income Strategies LLC bought a new stake in Adaptive Biotechnologies during the 3rd quarter worth about $30,000. Smartleaf Asset Management LLC increased its position in shares of Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after acquiring an additional 3,371 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Adaptive Biotechnologies in the first quarter valued at about $93,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Adaptive Biotechnologies during the second quarter worth about $134,000. Finally, Keybank National Association OH acquired a new position in Adaptive Biotechnologies during the third quarter valued at approximately $155,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $15.39 on Tuesday. The firm has a market cap of $2.35 billion, a P/E ratio of -38.47 and a beta of 2.18. Adaptive Biotechnologies Corporation has a 52 week low of $6.26 and a 52 week high of $20.76. The firm’s 50-day simple moving average is $16.91 and its 200 day simple moving average is $15.64.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same period last year, the business posted ($0.23) earnings per share. The business’s revenue for the quarter was up 51.0% compared to the same quarter last year. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ADPT. JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Morgan Stanley assumed coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. Guggenheim boosted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wall Street Zen raised shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 124,998 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.44, for a total value of $2,304,963.12. Following the transaction, the chief executive officer directly owned 2,459,245 shares of the company’s stock, valued at $45,348,477.80. This represents a 4.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Kyle Piskel sold 2,145 shares of the stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $18.46, for a total value of $39,596.70. Following the transaction, the chief financial officer owned 216,637 shares in the company, valued at $3,999,119.02. The trade was a 0.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 906,556 shares of company stock valued at $16,143,664. Company insiders own 6.40% of the company’s stock.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.